相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting
Elizabeth George et al.
CURRENT OPINION IN ANESTHESIOLOGY (2010)
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting
Tong J. Gan et al.
ANESTHESIA AND ANALGESIA (2007)
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
Ian Olver et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2007)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
J Herrstedt et al.
CANCER (2005)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
DG Warr et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant
M Bergström et al.
BIOLOGICAL PSYCHIATRY (2004)
An oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy
K Pendergrass et al.
DRUGS OF TODAY (2004)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Clinical biomarkers in drug discovery and development
R Frank et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting - Results from a randomized, double-blind, placebo-controlled trial in Latin America
S Poli-Bigelli et al.
CANCER (2003)
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
PJ Hesketh et al.
EUROPEAN JOURNAL OF CANCER (2003)
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
SP Chawla et al.
CANCER (2003)
Efficient synthesis of NK1 receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation
KMJ Brands et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Central neurocircuitry associated with emesis
PJ Hornby
AMERICAN JOURNAL OF MEDICINE (2001)
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
V Cocquyt et al.
EUROPEAN JOURNAL OF CANCER (2001)
Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs
JJ Hale et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
FD Tattersall et al.
NEUROPHARMACOLOGY (2000)
分享论文
